Back
Science

AI Tool Developed to Predict Cardiac Risks in Cancer Patients Post-Heart Attack

Generated on: Last updated: 3 sources
View source

New AI Tool ONCO-ACS to Personalize Care for Cancer Patients Post-Heart Attack

An international research team, led by the University of Zurich (UZH), has developed ONCO-ACS, an artificial intelligence (AI)-powered risk prediction model. This groundbreaking tool is specifically designed for cancer patients who have experienced a heart attack, aiming to predict the likelihood of adverse events and to personalize treatment strategies.

Its development addresses a long-standing gap in clinical guidance for this specific patient population.

Addressing a Critical Gap in Patient Care

Cancer patients who suffer a heart attack face complex and elevated risks, which have historically complicated their clinical treatment. These individuals have often been excluded from clinical trials and standard risk assessment tools, leading to a significant lack of standardized care guidelines.

Researchers have consistently highlighted the urgent need for more accurate tools to assess individual risk profiles for targeted treatment within this vulnerable group.

Groundbreaking Study Reveals High Risks

The development of ONCO-ACS is rooted in an extensive study published in The Lancet. The research meticulously analyzed data from over one million heart attack patients across England, Sweden, and Switzerland, a comprehensive cohort that included more than 47,000 individuals with cancer.

The study's findings painted a challenging prognosis for cancer patients following a heart attack:

  • Approximately one in three died within six months.
  • About one in 14 experienced a major bleeding event.
  • One in six had another heart attack, stroke, or cardiovascular death.

Introducing ONCO-ACS: An AI-Powered Solution

ONCO-ACS stands as the first risk prediction model specifically tailored for cancer patients who have suffered a heart attack.

The tool utilizes artificial intelligence to integrate cancer-specific factors with standard clinical data. Its primary purpose is to predict the likelihood of death, major bleeding, or another cardiac event within a six-month period.

The research underscores the profound interconnectedness of cancer and cardiovascular disease, which have traditionally often been treated as separate entities. It notes that cancer patients' risk of bleeding or arterial blood clotting can vary based on tumor characteristics. This variability directly influences the type of anti-platelet medication required for secondary prevention after an acute event, highlighting the need for personalized approaches.

Transforming Clinical Practice and Future Research

The ONCO-ACS tool is intended to provide clinicians with vital data to inform personalized treatment strategies, allowing for a more informed balance of potential benefits against risks. It aims to assist doctors in determining which patients may benefit most from invasive procedures and intensive drug therapy, and which individuals might be at higher risk of harm from such interventions.

Researchers anticipate that the ONCO-ACS score will be integrated into clinical practice to guide crucial decisions regarding catheter-based treatment and antiplatelet therapy. The tool is also expected to inform the design of future clinical trials, with the ultimate goal of improving outcomes for cancer patients following a heart attack. Its contribution is considered a significant step towards personalized medicine, accounting for the combined complexities of cancer and heart disease.